Seasonal Variability of Severe Asthma Exacerbations and Clinical Benefit from Lebrikizumab

Publication date: Available online 24 February 2017
Source:Journal of Allergy and Clinical Immunology
Author(s): Tracy L. Staton, Joseph R. Arron, Julie Olsson, Cécile TJ. Holweg, John G. Matthews, David F. Choy
Post-hoc analyses of two Phase III studies of lebrikizumab in moderate to severe asthma suggest that IL-13 inhibition is effective at preventing seasonal exacerbations in subjects with high blood eosinophil counts. Further work is required to understand and treat exacerbations that are independent of seasonal and Type 2 pathway factors.



http://ift.tt/2meQZXo